Publications by authors named "E Kerver"
Article Synopsis
- Patients with colorectal cancer and liver-only metastases showed improved outcomes when treated with FOLFOXIRI and bevacizumab compared to FOLFIRI and bevacizumab or with panitumumab, especially regarding progression-free survival and resection rates.
- The CAIRO5 trial involved 530 patients with initially unresectable liver metastases from colorectal cancer, evaluated across numerous centers in the Netherlands and Belgium, focusing on different treatment combinations based on tumor genetics.
- While more effective responses were observed with certain treatments, there was an increase in toxic side effects, particularly in specific genetic tumor variants like RAS/BRAFV600E.
Article Synopsis
- Immune checkpoint inhibition (ICI) combined with chemotherapy is the standard treatment for stage II-III triple-negative breast cancer, but the effectiveness of ICI alone remains unclear.
- The adaptive BELLINI trial found that short-term ICI treatments led to immune activation in a significant portion of patients, correlating immune response with tumor-infiltrating lymphocytes.
- A new cohort is being studied with patients who have high levels of these lymphocytes; early results show a notable rate of major and complete pathological responses post-treatment, suggesting that neoadjuvant ICI could be a promising approach without chemotherapy.
Purpose: The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable (dMMR/MSI) tumors, and in-depth biomarker analyses were performed to inform precision immunotherapy approaches.
Patients And Methods: Patients with dMMR/MSI tumors who exhausted standard-of-care treatment options were enrolled in the Drug Rediscovery Protocol, a pan-cancer clinical trial that treats patients with cancer based on their tumor molecular profile with off-label anticancer drugs (NCT02925234). Patients received nivolumab (four cycles of 240 mg every 2 weeks, thereafter 480 mg every 4 weeks).
Article Synopsis
- * Out of 24 patients, 46% showed clinical benefit, with a significant number achieving an objective response, and the overall treatment was considered safe with no unexpected side effects.
- * Whole genome sequencing helped identify potential resistance reasons in some patients, reinforcing the clinical significance of targeted therapy for HER2+mCRC.
Background: In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment de-escalation or escalation could be considered remains an unmet need. We evaluated the prognostic value of histopathologic traits in a unique cohort of young, (neo)adjuvant chemotherapy-naïve patients with early-stage (stage I or II), node-negative TNBC and long-term follow-up, in relation to stromal tumor-infiltrating lymphocytes (sTILs) for which the prognostic value was recently reported.
View Article and Find Full Text PDF